Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.
ADVANCED SEARCH
Log in
Top
Current Fungal Infection Reports
Published in: Current Fungal Infection Reports 3/2020

01-09-2020 | Micafungin | Pharmacology and Pharmacodynamics of Antifungal Agents (J Amsden,, Section Editor)

Antifungal Penetration and Distribution into Organs and Tissue

Authors: Kayla R. Stover, John D. Cleary

Published in: Current Fungal Infection Reports | Issue 3/2020

Login to get access

Abstract

Purpose of Review

Properties of penetration of antifungals into the body compartments have been reviewed extensively by Felton et al. in 2014, so the goal of this review was to identify new data, including information on ibrexafungerp and rezafungin, in order to provide an updated pharmacotherapy approach in difficult-to-treat infections.

Recent Findings

Along with early identification and early initiation of treatment, assuring sufficient distribution into the infected site is essential for successful therapy. Although there are a limited number, the penetration and distribution of antifungals into organs and tissue are widely variable between agents and classes, and can be affected by factors such as weight, genetics, comorbidities, and inflammation.

Summary

Clinicians should be aware of the challenges of tissue and organ penetration. Using existing human and animal data can help assure that penetration will be sufficient with the chosen antifungal prior to initiating therapy.
Literature
1.
Vanstraelen K, Wauters J, Vercammen I, de Loor H, Maertens J, Lagrou K, et al. Impact of hypoalbuminemia on voriconazole pharmacokinetics in critically ill adult patients. Antimicrob Agents Chemother. 2014;58:6782–9.PubMedPubMedCentral
2.
Allegra S, Fatiguso G, De Francia S, Favata F, Pirro E, Carcieri C, et al. Evaluation of posaconazole pharmacokinetics in adult patients with invasive fungal infection. Biomedicines. 2017;5:e66.PubMed
3.
Desai A, Kovanda L, Kowalski D, Lu Q, Townsend R, Bonate PL. Population pharmacokinetics of isavuconazole from phase 1 and phase 3 (SECURE) trials in adults and target attainment in patients with invasive infections due to Aspergillus and other filamentous fungi. Antimicrob Agents Chemother. 2016;60:5483–91.PubMedPubMedCentral
4.
Wang HF, Qiu F, Wu X, Fang J, Crownover P, Korth-Bradley J, et al. Steady-state pharmacokinetics of sirolimus in stable adult Chinese renal transplant patients. Clin Pharmacol Drug Dev. 2014;3:235–41.PubMed
5.
van Wanrooy MJ, Span LF, Rodgers MG, van den Heuvel ER, Uges DR, van der Werf TS, et al. Inflammation is associated with voriconazole trough concentrations. Antimicrob Agents Chemother. 2014;58:7098–101.PubMedPubMedCentral
6.
Encalada Ventura MA, van Wanrooy MJ, Span LF, Rodgers MG, van den Heuvel ER, Uges DR, et al. Longitudinal analysis of the effect of inflammation on voriconazole trough concentrations. Antimicrob Agents Chemother. 2016;60:2727–31.PubMedPubMedCentral
7.
Hall RG 2nd, Swancutt MA, Meek C, Leff R, Gumbo T. Weight drives caspofungin pharmacokinetic variability in overweight and obese people: fractal power signatures beyond two-thirds or three-fourths. Antimicrob Agents Chemother. 2013;57:2259–64.PubMedPubMedCentral
8.
Lin XB, Li ZW, Yan M, Zhang BK, Liang W, Wang F, et al. Population pharmacokinetics of voriconazole and CYP2C19 polymorphisms for optimizing dosing regimens in renal transplant recipients. Br J Clin Pharmacol. 2018;84:1587–97.PubMedPubMedCentral
9.
•• Felton T, Troke PF, Hope WW. Tissue penetration of antifungal agents. Clin Microbiol Rev. 2014;27:68–88 First comprehensive review of distribution of antifungal agents into tissues with information available at that time. PubMedPubMedCentral
10.
• Zhao Y, Prideaux B, Baistrocchi S, Sheppard DC, Perlin DS. Beyond tissue concentrations: antifungal penetration at the site of infection. Med Mycol. 2019;57:S161–7 Review of processes used to ascertain drug concentrations and perspectives on upcoming technologies that will be beneficial in the future. PubMedPubMedCentral
11.
Zhao Y, Prideaux B, Nagasaki Y, Lee MH, Chen PY, Blanc L, et al. Unraveling drug penetration of echinocandin antifungals at the site of infection in an intra-abdominal abscess model. Antimicrob Agents Chemother. 2017;61:e01009–17.PubMedPubMedCentral
12.
Brammer KW, Farrow PR, Faulkner JK. Pharmacokinetics and tissue penetration of fluconazole in humans. Rev Infect Dis. 1990;12:S318–26.PubMed
13.
Prentice AG, Glasmacher A. Making sense of itraconazole pharmacokinetics. J Antimicrob Chemother. 2005;56:e17–22.
14.
Astellas Pharma US, Inc. (2019). Cresemba (isavuconazonium sulfate): prescribing information. Northbrook, IL.
15.
•• Schmitt-Hoffman AH, Kato K, Townsend R, Potchoiba MJ, Hope WW, Andews D, et al. Tissue distribution and elimination of isavuconazole following single and repeat oral-dose administration of issavuconazonium sulfate to rats. Antimicrob Agents Chemother. 2017;61:e01292–17 Evaluation of tissue and fluid distribution and concentrations with isavuconazole after single and multiple oral doses.
16.
•• Blennow O, Eliasson E, Pettersson T, Pohanka A, Szakos A, El-Serafi I, et al. Posaconazole concentrations in human tissues after allogeneic stem cell transplantation. Antimicrob Agents Chemother. 2014;58:4941–3 Evaluation of posaconazole tissue concentrations taken after autopsy and compared to plasma concentrations collected prior to death. PubMedPubMedCentral
17.
Lewis RE. Importance of pharmacokinetic considerations for selecting therapy in the treatment of invasive fungal infections. Am J Ther. 2012;19(1):51–63.PubMed
18.
Li Y, Theuretzbacher U, Clancy CJ, Nguyen MH, Derendorf H. Pharmacokinetic/pharmacodynamic profile of posaconazole. Clin Pharmacokinet. 2010;49:379–96.PubMed
19.
Hariprasad SM, Mieler WF, Holz ER, Gao H, Kim JE, Chi J. Determination of vitreous, aqueous, and plasma concentration of orally administered voriconazole in humans. Arch Ophthalmol. 2004;122(1):42–7.PubMed
20.
Heng SC, Snell GI, Levvey B, Keating D, Westall GP, Williams TJ, et al. Relationship between trough plasma and epithelial lining fluid concentrations of voriconazole in lung transplant recipients. Antimicrob Agents Chemother. 2013;57:4581–3.PubMedPubMedCentral
21.
Damle B, Stogniew M, Dowell J. Pharmacokinetics and tissue distribution of anidulafungin in rats. Antimicrob Agents Chemother. 2008;52:2673–6.PubMedPubMedCentral
22.
Roerig, Division of Pfizer Inc. Eraxis (anidulafungin): prescribing information. New York, NY, 2006.
23.
Stone FA, Fung HB, Kirschenbaum HL. Caspofungin: an echinocandin antifungal agent. Clin Ther. 2002;24:351–77.PubMed
24.
Sasaki J, Yamanouchi S, Kudo D, Endo T, Nomura R, Takuma K. Micafungin concentrations in the plasma and burn eschar of severely burned patients. Antimicrob Agents Chemother. 2012;56(2):1113–5.PubMedPubMedCentral
25.
Astellas Pharma US, Inc. Mycamine (micafungin sodium): prescribing information. Northbrook, IL, 2016.
26.
• Lakota EA, Ong V, Flanagan S, Rubino CM. Population pharmacokinetic analyses for rezafungin (CD101) efficacy using phase 1 data. Antimicrob Agents Chemother. 2018;62(6) Early report of population pharmacokinetics of rezafungin (CD101) that presents information such as volume of distribution and clearance.
27.
Sofjan AK, Mitchell A, Shah DN, Nguyen T, Sim M, Trojcak A, et al. Rezafungin (CD101), a next-generation echinocandin: a systematic literature review and assessment of possible place in therapy. J Global Antimicrob Res. 2018;14:58–64.
28.
Wring SA, Randolph R, Park S, Abruzzo G, Chen Q, Flattery A, et al. Preclinical pharmacokinetics and pharmacodynamic target of SCY-078, a first-in-class orally active antifungal glucan synthesis inhibitor, in murine models of disseminated candidiasis. Antimicrob Agents Chemother. 2017;61:e02068–16.PubMedPubMedCentral
29.
Adedoyin A, Bernardo JF, Swenson CE, Bolsack LE, Horwith G, DeWit S, et al. Pharmacokinetic profile of ABELCET (amphotericin B lipid complex injection): combined experience from phase I and phase II studies. Antimicrob Agents Chemother. 1997;41:2201–8.PubMedPubMedCentral
30.
Bekersky I, Fielding RM, Dressler DE, Lee JW, Buell DN, Walsh TJ. Pharmacokinetics, excretion, and mass balance of liposomal amphotericin B (AmBisome) and amphotericin B deoxycholate in humans. Antimicrob Agents Chemother. 2002;46:828–33.PubMedPubMedCentral
31.
Stockmann C, Constance JE, Roberts JK, Olson J, Doby EH, Ampofo K, et al. Pharmacokinetics and pharmacodynamics of antifungals in children and their clinical implications. Clin Pharmacokinet. 2014;53:429–54.PubMedPubMedCentral
32.
• Welte R, Eller P, Lorenz I, Joannidis M, Bellmann R. Anidulafungin pharmacokinetics in ascites fluid and pleural effusion of critically ill patients. Antimicrob Agents Chemother. 2018;62:e02326–17 One of the first evaluations of anidulafungin concentrations specifically in ascites fluid and pleural effusions of critically ill patients. PubMedPubMedCentral
33.
•• Wring S, Borroto-Esoda K, Solon E, Angulo D. SCY-078, a novel fungicidal agent, demonstrates distribution to tissues associated with fungal infections during mass balance studies with intravenous and oral [(14)C]SCY-078 in albino and pigmented rats. Antimicrob Agents Chemother. 2019;63:e02119–8 First comprehensive evaluation of tissue and fluid distribution and concentrations with ibrexafungerp after intravenous and oral doses. PubMedPubMedCentral
34.
Stott KE, Beardsley J, Whalley S, Kibengo FM, Mai NTH, Tung NLN, et al. Population pharmacokinetic model and meta-analysis of outcomes of amphotericin B deoxycholate use in adults with cryptococcal meningitis. Antimicrob Agents Chemother. 2018;62:e02526–17.PubMedPubMedCentral
35.
Lestner JM, Groll AH, Aljayyoussi G, Seibel NL, Shad A, Gonzalez C, et al. Population pharmacokinetics of liposomal amphotericin B in immunocompromised children. Antimicrob Agents Chemother. 2016;60:7340–6.PubMedPubMedCentral
36.
Rivosecchi RM, Samanta P, Demehin M, Nguyen MH. Pharmacokinetics of azole antifungals in cystic fibrosis. Mycopathologia. 2018;183:139–50.PubMed
37.
Carrasco-Portugal Mdel C, Flores-Murrieta FJ. Gender differences in the oral pharmacokinetics of fluconazole. Clin Drug Investig. 2007;27:851–5.PubMed
38.
Alobaid AS, Wallis SC, Jarrett P, Starr T, Stuart J, Lassig-Smith M, et al. Effect of obesity on the population pharmacokinetics of fluconazole in critically ill patients. Antimicrob Agents Chemother. 2016;60:6550–7.PubMedPubMedCentral
39.
Momper JD, Capparelli EV, Wade KC, Kantak A, Dhanireddy R, Cummings JJ, et al. Population pharmacokinetics of fluconazole in premature infants with birth weights less than 750 grams. Antimicrob Agents Chemother. 2016;60:5539–45.PubMedPubMedCentral
40.
Han S, Kim J, Yim H, Hur J, Song W, Lee J, et al. Population pharmacokinetic analysis of fluconazole to predict therapeutic outcome in burn patients with Candida infection. Antimicrob Agents Chemother. 2013;57:1006–11.PubMedPubMedCentral
41.
Kim H, Shin D, Kang HJ, Yu KS, Lee JW, Kim SJ, et al. Successful empirical antifungal therapy of intravenous itraconazole with pharmacokinetic evidence in pediatric cancer patients undergoing hematopoietic stem cell transplantation. Clin Drug Investig. 2015;35:437–46.PubMed
42.
Wu X, Clancy CJ, Rivosecchi RM, Zhao W, Shields RK, Marini RV, et al. Pharmacokinetics of intravenous isavuconazole in solid-organ transplant recipients. Antimicrob Agents Chemother. 2018;62:e01643–18.PubMedPubMedCentral
43.
Kovanda LL, Desai AV, Lu Q, Townsend RW, Akhtar S, Bonate P, et al. Isavuconazole population pharmacokinetic analysis using nonparametric estimation in patients with invasive fungal disease (results from the VITAL study). Antimicrob Agents Chemother. 2016;60:4568–76.PubMedPubMedCentral
44.
Arsie PS, Iavarone M, Cozzi V, Lampertico P, Cattaneo D. High isavuconazole plasma levels in a patient with possible invasive pulmonary aspergillosis and cirrhosis. Eur J Clin Pharmacol. 2018;74:1089–90.PubMed
45.
Launay M, Roux A, Beaumont L, Douvry B, Lecuyer L, Douez E, et al. Posaconazole tablets in real-life lung transplantation: impact on exposure, drug-drug interactions, and drug management in lung transplant patients, including those with cystic fibrosis. Antimicrob Agents Chemother. 2018;62:e02061–17.PubMedPubMedCentral
46.
Tang D, Song BL, Yan M, Zou JJ, Zhang M, Zhou HY, et al. Identifying factors affecting the pharmacokinetics of voriconazole in patients with liver dysfunction: a population pharmacokinetic approach. Basic Clin Pharmacol Toxicol. 2019;125:34–43.PubMed
47.
Ruiz J, Gordon M, Villarreal E, Peruccioni M, Marques MR, Poveda-Andres JL, et al. Impact of voriconazole plasma concentrations on treatment response in critically ill patients. J Clin Pharm Ther. 2019;44:572–8.PubMed
48.
Boonstra JM, van der Elst KC, Veringa A, Jongedijk EM, Bruggemann RJ, Koster RA, et al. Pharmacokinetic properties of micafungin in critically ill patients diagnosed with invasive candidiasis. Antimicrob Agents Chemother. 2017;61:e01398–17.PubMedPubMedCentral
49.
Bruggemann RJ, Middel-Baars V, de Lange DW, Colbers A, Girbes AR, Pickkers P, et al. Pharmacokinetics of anidulafungin in critically ill intensive care unit patients with suspected or proven invasive fungal infections. Antimicrob Agents Chemother. 2017;61:e01894–16.PubMedPubMedCentral
50.
Lempers VJ, Schouten JA, Hunfeld NG, Colbers A, van Leeuwen HJ, Burger DM, et al. Altered micafungin pharmacokinetics in intensive care unit patients. Antimicrob Agents Chemother. 2015;59:4403–9.PubMedPubMedCentral
51.
Lempers VJ, van Rongen A, van Dongen EP, van Ramshorst B, Burger DM, Aarnoutse RE, et al. Does weight impact anidulafungin pharmacokinetics? Clin Pharmacokinet. 2016;55:1289–94.PubMedPubMedCentral
52.
Kurland S, Kurland S, Furebring M, Löwdin E, Eliasson E, Nielsen EI, et al. Pharmacokinetics of caspofungin in critically ill patients in relation to liver dysfunction: differential impact of plasma albumin and bilirubin levels. Antimicrob Agents Chemother. 2019;63:e02466–18.PubMedPubMedCentral
53.
van der Elst KC, Bruggemann RJ, Rodgers MG, Alffenaar JW. Plasma concentrations of caspofungin at two different dosage regimens in a patient with hepatic dysfunction. Transpl Infect Dis. 2012;14:440–3.PubMed
54.
Farowski F, Cornely OA, Vehreschild JJ, Wiesen M, Steinbach A, Vehreschild MJ, et al. Intracellular concentrations of anidulafungin in different compartments of the peripheral blood. Int J Antimicrob Agents. 2013;41:379–82.PubMed
55.
Farowski F, Cornely OA, Vehreschild JJ, Bauer T, Hartmann P, Steinbach A, et al. Intracellular concentrations of micafungin in different cellular compartments of the peripheral blood. Int J Antimicrob Agents. 2012;39:228–31.PubMed
56.
Cleary JD, Wasan K. Amphotericin B: A new look at cellular binding. Open Antimicrobial Agents. 2011;3:30–6.
57.
Wijnant GJ, Van Bocxlaer K, Yardley V, Harris A, Murdan S, Croft SL, et al. Relation between skin pharmacokinetics and efficacy in ambisome treatment of murine cutaneous leishmaniasis. Antimicrob Agents Chemother. 2018;62(3).
58.
Conte JE Jr, DeVoe C, Little E, Golden JA. Steady-state intrapulmonary pharmacokinetics and pharmacodynamics of posaconazole in lung transplant recipients. Antimicrob Agents Chemother. 2010;54:3609–13.PubMedPubMedCentral
59.
Conte JE Jr, Golden JA, Krishna G, McIver M, Little E, Zurlinden E. Intrapulmonary pharmacokinetics and pharmacodynamics of posaconazole at steady state in healthy subjects. Antimicrob Agents Chemother. 2009;53:703–7.PubMed
60.
Farowski F, Cornely OA, Vehreschild JJ, Hartmann P, Bauer T, Steinbach A, et al. Intracellular concentrations of posaconazole in different compartments of the peripheral blood. Antimicrob Agents Chemother. 2010;54:2928–31.PubMedPubMedCentral
61.
• Lee A, Prideaux B, Zimmerman M, Carter C, Barat S, Angulo D, et al. Penetration of ibrexafungerp (formerly SCY-078) at the site of action in an intra-abdominal candidiasis mouse model. Antimicrob Agents Chemother. 2019:02268–19 Evaluation of ibrexafungerp in an infection model of intra-abdominal infections that supplements tissue distribution data in healthy animals that was published previously.
62.
•• Ong V, James KD, Smith S, Krishnan BR. Pharmacokinetics of the novel echinocandin CD101 in multiple animal species. Antimicrob Agents Chemother. 2017;61:e01626–16 First report of population pharmacokinetics of rezafungin (CD101) in mice, rats, dogs, monkeys, and chimpanzees that presents information such as volume of distribution, maximum concentrations, AUC, and clearance and also presents information regarding tissue distribution to the liver, kidneys, and lungs. PubMedPubMedCentral
63.
• Stott KE, Hope W. Pharmacokinetics-pharmacodynamics of antifungal agents in the central nervous system. Expert Opin Drug Metab Toxicol. 2018;14:803–15 Thorough evaluation of antifungal penetration and utility in CNS infections, including an assessment of their penetration in relation to molecule size and weight. PubMed
64.
Stott KE, Beardsley J, Kolamunnage-Dona R, Castelazo AS, Kibengo FM, Mai NTH, et al. Population pharmacokinetics and cerebrospinal fluid penetration of fluconazole in adults with cryptococcal meningitis. Antimicrob Agents Chemother. 2018;62:e00885–18.PubMedPubMedCentral
65.
Auriti C, Falcone M, Ronchetti MP, Goffredo BM, Cairoli S, Crisafulli R, et al. High-dose micafungin for preterm neonates and infants with invasive and central nervous system candidiasis. Antimicrob Agents Chemother. 2016;60:7333–9.PubMedPubMedCentral
66.
Henry ME, Bolo NR, Zuo CS, Villafuerte RA, Cayetano K, Glue P, et al. Quantification of brain voriconazole levels in healthy adults using fluorine magnetic resonance spectroscopy. Antimicrob Agents Chemother. 2013;57:5271–6.PubMedPubMedCentral
67.
Furudate A, Hirose S, Abe K, Kawashima A, Hashimoto K, Yamazaki S, et al. Infantile Aspergillus fumigatus ventriculitis successfully treated with monitoring of plasma and cerebrospinal fluid voriconazole concentration level. J Infect Chemother. 2020;26:132–5.PubMed
68.
Caudle KE, Inger AG, Butler DR, Rogers PD. Echinocandin use in the neonatal intensive care unit. Ann Pharmacother. 2012;46:108–16.PubMed
69.
Strenger V, Farowski F, Muller C, Hofer N, Dornbusch HJ, Sperl D, et al. Low penetration of caspofungin into cerebrospinal fluid following intravenous administration of standard doses. Int J Antimicrob Agents. 2017;50:272–5.PubMed
70.
Lee A, Prideaux B, Lee MH, Zimmerman M, Dolgov E, Perlin DS, et al. Tissue distribution and penetration of isavuconazole at the site of infection in experimental invasive aspergillosis in mice with underlying chronic granulomatous disease. Antimicrob Agents Chemother. 2019;63:e00524–19.PubMedPubMedCentral
71.
Savani DV, Perfect JR, Cobo LM, Durack DT. Penetration of new azole compounds into the eye and efficacy in experimental Candida endophthalmitis. Antimicrob Agents Chemother. 1987;31:6–10.PubMedPubMedCentral
72.
Mochizuki K, Sawada A, Suemori S, Kawakami H, Niwa Y, Kondo Y, et al. Intraocular penetration of intravenous micafungin in inflamed human eyes. Antimicrob Agents Chemother. 2013;57(8):4027–30.PubMedPubMedCentral
73.
Azeredo FJ, de Araujo BV, Haas SE, Torres B, Pigatto M, de Andrade C, et al. Comparison of fluconazole renal penetration levels in healthy and Candida albicans-infected Wistar rats. Antimicrob Agents Chemother. 2012;56:5852–7.PubMedPubMedCentral
74.
Walsh TJ, Foulds G, Pizzo PA. Pharmacokinetics and tissue penetration of fluconazole in rabbits. Antimicrob Agents Chemother. 1989;33:467–9.PubMedPubMedCentral
75.
Weiler S, Fiegl D, MacFarland R, Stienecke E, Bellmann-Weiler R, Dunzendorfer S, et al. Human tissue distribution of voriconazole. Antimicrob Agents Chemother. 2011;55:925–8.PubMed
76.
Krieter P, Flannery B, Musick T, Gohdes M, Martinho M, Courtney R. Disposition of posaconazole following single-dose oral administration in healthy subjects. Antimicrob Agents Chemother. 2004;48:3543–51.PubMedPubMedCentral
77.
Livermore J, Hope W. Evaluation of the pharmacokinetics and clinical utility of isavuconazole for treatment of invasive fungal infections. Expert Opin Drug Metab Toxicol. 2012;8:759–65.PubMed
78.
Sandison T, Ong V, Lee J, Thye D. Safety and pharmacokinetics of CD101 IV, a novel echinocandin, in healthy adults. Antimicrob Agents Chemother. 2017;61:e01627–16.PubMedPubMedCentral
79.
Anderson CU, Sonderskov LD, Bendstrup E, Voldby N, Cass L, Ayrton J, et al. Voriconazole concentrations in plasma and epithelial lining fluid after inhalation and oral treatment. Basic Clin Pharmacol Toxicol. 2017;121:430–4.
80.
Sevedmousavi S, Bruggemann RJ, Melchers WJ, Verweij PE, Mouton JW. Intrapulmonary posaconazole penetration at the infection site in an immunosuppressed murine model of invasive pulmonary aspergillosis receiving oral prophylactic regimens. Antimicrob Agents Chemother. 2014;58:2964–7.
81.
Thakuria L, Packwood K, Firouzi A, Rogers P, Soresi S, Habibi-Parker K, et al. A pharmacokinetic analysis of posaconazole oral suspension in the serum and alveolar compartment of lung transplant recipients. Int J Antimicrob Agents. 2016;47:69–76.PubMed
82.
Petraitis V, Petraitiene R, Moradi PW, Strauss GE, Katragkou A, Kovanda LL, et al. Pharmacokinetics and concentration-dependent efficacy of isavuconazole for treatment of experimental invasive pulmonary aspergillosis. Antimicrob Agents Chemother. 2016;60:2718–26.PubMedPubMedCentral
83.
Hu G, Caza M, Cadieux B, Bakkeren E, Do E, Jung WH. The endosomal sorting complex required for transport machinery influences haem uptake and capsule elaboration in Cryptococcus neoformans. Mol Microbiol. 2015;96(5):973–92.PubMedPubMedCentral
84.
Akers KS, Rowan MP, Niece KL, Graybill JC, Mende K, Chung KK. Antifungal wound penetration of amphotericin and voriconazole in combat-related injuries: case report. BMC Infect Dis. 2015;15(752777778):184.PubMedPubMedCentral
85.
Sasaki J, Yamanouchi S, Sato Y, Abe S, Shinozawa Y, Kishino S. Penetration of micafungin into the burn eschar in patients with severe burns. Eur J Drug Metab Pharmacokinet. 2014;39(2):93–7.PubMed
Metadata
Title
Antifungal Penetration and Distribution into Organs and Tissue
Authors
Kayla R. Stover
John D. Cleary
Publication date
01-09-2020
Publisher
Springer US
Published in
Current Fungal Infection Reports / Issue 3/2020
Print ISSN: 1936-3761
Electronic ISSN: 1936-377X
DOI
https://doi.org/10.1007/s12281-020-00390-7

Other articles of this Issue 3/2020

Current Fungal Infection Reports 3/2020 Go to the issue

Fungal Infections of Skin and Subcutaneous Tissue (A Bonifaz and M Pereira, Section Editors)

Cutaneous Fungal Infections in Left Ventricular Assist Device Recipients

Pharmacology and Pharmacodynamics of Antifungal Agents (J Amsden,, Section Editor)

Implications of Evolving and Emerging Pharmacokinetic-Pharmacodynamic Research for Triazoles and Echinocandins

Fungal Infections of Skin and Subcutaneous Tissue (A Bonifaz and M Pereira, Section Editors)

Candida Onychomycosis: an Old Problem in Modern Times

Clinical Mycology Lab Issues (S Cordoba, Section Editor)

Innovative Approaches for Histoplasma Detection

Clinical Pathology (S Challa, Section Editor)

Sino-Orbital Invasive Fungal Infections in Immunocompetent Hosts

Fungal Infections of Skin and Subcutaneous Tissue (A Bonifaz and M Pereira, Section Editors)

White Piedra, a Rare Superficial Mycosis: an Update
Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Reserve your place

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin
Prof. Florian Limbourg
Prof. Anoop Chauhan
Developed by: Springer Medicine
Obesity Clinical Trial Summary

At a glance: The STEP trials

Read more

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine

Highlights from the ACC 2024 Congress

Year in Review: Pediatric cardiology

Pediatric Cardiology Video

Watch Dr. Anne Marie Valente present the last year's highlights in pediatric and congenital heart disease in the official ACC.24 Year in Review session.

Year in Review: Pulmonary vascular disease

Cardiopulmonary Comorbidity Video

The last year's highlights in pulmonary vascular disease are presented by Dr. Jane Leopold in this official video from ACC.24.

Year in Review: Valvular heart disease

Valvular Heart Disease Video

Watch Prof. William Zoghbi present the last year's highlights in valvular heart disease from the official ACC.24 Year in Review session.

Year in Review: Heart failure and cardiomyopathies

Heart Failure Video

Watch this official video from ACC.24. Dr. Biykem Bozkurt discusses last year's major advances in heart failure and cardiomyopathies.

ACC 2024 Congress Coverage

Year in Review: Heart failure and cardiomyopathies

Heart Failure Video

Watch this official video from ACC.24. Dr. Biykem Bozkurt discusses last year's major advances in heart failure and cardiomyopathies.

Watch now

Semaglutide benefits people with type 2 diabetes and obesity-related heart failure

16-04-2024 Type 2 Diabetes News

Incentivised to exercise

11-04-2024 Lifestyle Modifications News

New intervention for STEMI-related cardiogenic shock

10-04-2024 Myocardial Infarction News

» View more highlights on the ACC 2024 congress hub page

Image Credits